According to a new report published by K D Market Insights, titled, “DNA Methylation Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global DNA methylation market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. Increasing applications of DNA methylation analysis in various fields, including cancer research, diagnostics, personalized medicine, and epigenetics. Are the major factors augmenting the growth of the global DNA methylation market.
Factors such as the growing adoption of personalized medicine and precision oncology approaches fuels the demand for DNA methylation analysis. DNA methylation patterns can serve as valuable biomarkers for disease diagnosis, prognosis, and treatment response prediction, facilitating the development of targeted therapies are further expected to create ample growth opportunities for the global dna methylation market during the forecast period i.e., 2023-2032. Moreover, the advancements in sequencing technologies and bioinformatics are expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global DNA methylation market in 2022. The region is further projected to continue dominating in the market during the forecast period. Primarily driven by the United States. The region's presence of a vast network of manufacturing and research and development (R&D) facilities contribute to its market dominance.
According to product, the consumables segment accounted for the largest market share in the DNA methylation market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global DNA methylation market is segmented into technology, product, application, end-use and region. Based on technology, the market is bifurcated into PCR, microarray, sequencing. Based on product, it is classified into consumables, kits & reagents, enzymes, instruments & software. Based on application, it is classified into gene therapy, clinical research, diagnostics. Based on end use, it is classified into hospital & diagnostic laboratories, pharmaceutical & biotechnology companies, research & academia.
The global DNA methylation market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Neurotrophins Market
On the basis of product, the consumables segment accounted for the largest market share in the DNA methylation market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.On the basis of region, North America accounted for the largest share in the global DNA methylation market in 2022. The region is further projected to continue dominating in the market during the forecast period.On the basis of region, Asia Pacific is estimated to account for the second largest share in the market during the forecast period.Some of the major DNA methylation companies profiled in the report include New England Biolabs, Sysmex Corporation, Abcam plc, F. Hoffmann-La Roche Ltd, Diagenode Diagnostics S.A, Thermo Fisher Scientific Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Active Motif Inc, Illumina Inc, EpiGentek Group Inc, Pacific Biosciences Inc, Merck KGaA, Zymo Research Corporation, and PerkinElmer Inc.
Sign in to leave a comment.